Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Reata Pharmaceuticals, Inc. (RETA : NSDQ)

• Company Description    Reata Pharmaceuticals is a clinical-stage pharmaceutical company primarily focused on discovering, developing and commercializing small-molecule based innovative therapies for treating severe, life-threatening diseases with a few or no approved therapies. The company is developing its lead pipeline candidates - bardoxolone methyl (bardoxolone) and omaveloxolone for rare forms of chronic kidney disease (CKD) and neurological diseases, respectively. Number of Employees: 349

• Price / Volume Information    Yesterday's Closing Price: $27.68 Daily Weekly Monthly 20 Day Moving Average: 513,449 shares Shares Outstanding: 36.40 (millions) Market Capitalization: $1,007.66 (millions) Beta: 1.25 52 Week High: $153.41 52 Week Low: $20.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.88% 6.01% 12 Week 8.21% 18.97% Year To Date 4.97% 28.25%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5320 LEGACY DRIVE - PLANO,TX 75024 USA ph: 972-865-2219 fax: - ir@reatapharma.com http://www.reatapharma.com

• General Corporate Information    Officers J. Warren Huff - Chief Executive Officer and Chairman of the Board Manmeet S. Soni - Chief Operating Officer and Chief Financial Office Bhaskar Anand - Vice President and Chief Accounting Officer Martin W. Edward - Directors William D. McClellan - Directors Peer Information Reata Pharmaceuticals, Inc. (CORR.) Reata Pharmaceuticals, Inc. (RSPI) Reata Pharmaceuticals, Inc. (CGXP) Reata Pharmaceuticals, Inc. (BGEN) Reata Pharmaceuticals, Inc. (GTBP) Reata Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 75615P103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 36.40 Most Recent Split Date: (:1) Beta: 1.25 Market Capitalization: $1,007.66 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.90 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-8.34 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.89 Price/Cash Flow: - Price / Sales: 87.93 EPS Growth vs. Year Ago Period: -9.14% vs. Previous Quarter: 13.62% Sales Growth vs. Year Ago Period: -3.18% vs. Previous Quarter: -2.14% ROE 03/31/22 - -137.52 12/31/21 - -105.72 09/30/21 - -81.91 ROA 03/31/22 - -41.55 12/31/21 - -38.88 09/30/21 - -34.92 Current Ratio 03/31/22 - 12.32 12/31/21 - 11.05 09/30/21 - 5.95 Quick Ratio 03/31/22 - 12.32 12/31/21 - 11.05 09/30/21 - 5.95 Operating Margin 03/31/22 - -2,650.72 12/31/21 - -2,588.22 09/30/21 - -2,020.49 Net Margin 03/31/22 - -2,650.72 12/31/21 - -2,588.22 09/30/21 - -2,020.49 Pre-Tax Margin 03/31/22 - -2,654.25 12/31/21 - -2,592.13 09/30/21 - -2,026.45 Book Value 03/31/22 - 3.51 12/31/21 - 5.11 09/30/21 - 7.03 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©